Eisai President Warns Other Industries About Pharma M&A Risks
This article was originally published in PharmAsia News
Executive Summary
Commenting on recent acquisitions of Japanese domestic pharmaceutical companies by companies from different industries, Eisai President Haruo Naito welcomed the M&A activities as inflow of new investments to energize the industry. As the Japanese government has shown support for innovation and strengthened assistance for pharmaceutical research and development, foreign investments will be flowing in as well. But Naito also cautioned about the industrial risks. Because pharmaceutical research and development is inevitably costly and the success of a company lies in its abilities to develop and market new drugs, Naito said, no matter what industries the new entries come from, a risk-taking attitude is a must. (Click here for more - Japanese language) "President Of Eisai Haruo Naito: Pharmaceutical Development Costly" - Sankai News (3/25/08)